

## **David H. Johnson, MD, FACP** [1]



### **Cancer.Net Associate Editor: Lung Cancer**

University of Texas Southwestern Medical Center

David Johnson, MD, FACP, is the Donald W. Seldin Distinguished Chair in Internal Medicine and Chairman of the Department of Internal Medicine at the University of Texas Southwestern Medical Center. In 2004-2005, Dr. Johnson served as President of ASCO, during which time he helped advance ASCO's quality of care activity known as the Quality Oncology Practice Initiative (QOPI). He was also instrumental in establishing ASCO's Cancer Survivorship Program.

He is a member of the American Board of Internal Medicine (ABIM) Board of Directors and serves as the Chair of the ABIM Subspecialty Board for Medical Oncology. Dr. Johnson also has served on the Food and Drug Administration's Oncology Drug Advisory Committee, as chairman of the Thoracic Committee of the Eastern Cooperative Oncology Group, and on the Board of Directors of the National Comprehensive Cancer Network, the International Association for the Study of Lung Cancer, and the **LIVESTRONG** Foundation.

Dr. Johnson has authored more than 350 peer reviewed articles, 40 book chapters and edited four oncology textbooks. His research interests involve understanding the biology of lung cancer and improving the treatment of this and other solid tumors. He also played a key role in the development of the targeted drugs bevacizumab (Avastin) and erlotinib (Tarceva), both of which are now FDA-approved for the treatment of lung cancer.

In 2006 he received the Distinguished Southern Oncologist Award from the Southern Medical Society and the Statesman Award from ASCO in 2008. Presented annually, the Statesman Award recognizes individual ASCO members who have shown extraordinary volunteer service, dedication and commitment to ASCO, their hospital community and the patients they serve for at least 20 years. In 2009 he was elected to the Association of American Physicians.

Read more about [Dr. Johnson in a recent profile](#) [2].

Disclosure: In the past two years, Dr. Johnson served as a consultant/advisor for Pieris AG, GTx, miRNA Therapeutics, Peloton Therapeutics, the LIVE**STRONG** Foundation, and the American Board of Internal Medicine.

Last Updated: November 07, 2011

---

**Links:**

[1] <http://www.cancer.net/about-us/cancernet-editorial-board/associate-editors/david-h-johnson-md-facp>

[2] <http://www.cancer.net/node/24498>